Tags: Parkinsons disease | drug | rytary | carbidopa-levodopa

New Help for Parkinson's

Thursday, 08 Jan 2015 12:21 PM


Impax Laboratories Inc said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease.
Impax's shares rose 12 pct at $34.67 in premarket trading.
The FDA had previously rejected the drug, citing issues with the company's manufacturing plant in Hayward, California. The agency later raised concerns about Impax's factory in Taiwan.
Rytary is a long-acting capsule formulation of carbidopa-levodopa, the standard of care for Parkinson's
 

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
FDA-Approved-Drugs
Impax Laboratories Inc said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease.Impax's shares rose 12 pct at $34.67 in premarket trading. The FDA had previously rejected the drug, citing issues with the company's...
Parkinsons disease, drug, rytary, carbidopa-levodopa
70
2015-21-08
Thursday, 08 Jan 2015 12:21 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved